Percepta基因组分类器对多中心前瞻性研究中肺结节临床管理决策的影响
该前瞻性真实世界登记研究纳入35个美国中心中支气管镜检查无明确诊断的肺结节患者,分析Percepta基因组分类器结果对临床管理决策的影响。
要点
- Percepta阴性可使低/中危肺结节患者34.3%风险降级,73.9%转为监测。
- 风险降级后多数患者在12个月内避免侵入性操作。
核心结论
- Percepta基因组分类器对肺结节恶性风险降级可减少额外侵入性操作,且不延迟肺癌诊断时间。
研究设计与样本
- 前瞻性真实世界登记研究,覆盖35个美国中心,观察支气管镜检查无明确诊断后肺结节的医师管理。
- 分析纳入283例支气管镜检查无结论、有Percepta结果且经过 adjudicated 肺诊断并至少随访1年的患者。
主要发现
- 在临床医师原计划行后续侵入性操作的低/中危患者中,Percepta阴性使34.3%的病例恶性风险降级。
- 风险降级患者中73.9%的管理计划由侵入性操作转为监测,且多数在初始评估后12个月内避免操作。
临床怎么用
- 对支气管镜无明确诊断的低/中危肺结节患者,Percepta阴性结果可用于支持将侵入性操作计划转为监测。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The Percepta genomic classifier has been clinically validated as a complement to bronchoscopy for lung nodule evaluation. RESEARCH QUESTION: The goal of this study was to examine the impact on clinical management decisions of the Percepta result in patients with low- and intermediate-risk lung nodules. STUDY DESIGN AND METHODS: A prospective "real world" registry was instituted across 35 US centers to observe physician management of pulmonary nodules following a nondiagnostic bronchoscopy. To assess the impact on management decisions of the Percepta genomic classifier, a subset of patients was analyzed who had an inconclusive bronchoscopy for a pulmonary nodule, a Percepta result, and an adjudicated lung diagnosis with at least 1 year of follow-up. In this cohort, change in the decision to pursue additional invasive procedures following Percepta results was assessed. RESULTS: A total of 283 patients met the study eligibility criteria. In patients with a low/intermediate risk of malignancy for whom the clinician had designated a plan for a subsequent invasive procedure, a negative Percepta result down-classified the risk of malignancy in 34.3% of cases. Of these down-classified patients, 73.9% had a change in their management plan from an invasive procedure to surveillance, and the majority avoided a procedure up to 12 months following the initial evaluation. In patients with confirmed lung cancers, the time to diagnosis was not significantly delayed when comparing Percepta down-classified patients vs patients who were not down-classified (P = .58). INTERPRETATION: The down-classification of nodule malignancy risk with the Percepta test decreased additional invasive procedures without a delay in time to diagnosis among those with lung cancer.
引用
- Lee HJ, Mazzone P, Feller-Kopman D, et al. Impact of the Percepta Genomic Classifier on Clinical Management Decisions in a Multicenter Prospective Study. Chest. 2020. PMID: 32758562. doi:10.1016/j.chest.2020.07.067
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。